Nov 12, 2021 15:03 JST

Source: Eisai

Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer's Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced a presentation about exploring the use of plasma-based biomarkers in the Phase 3 AHEAD 3-45 study of lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody. AHEAD 3-45 is the first preclinical Alzheimer's disease (AD) trial to use these biomarkers to detect AD pathology and potentially accelerate the screening process. This presentation was made by The Alzheimer's Clinical Trial Consortium (ACTC) at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) conference, November 9-12, 2021 in Boston, Massachusetts and virtually.

The AHEAD 3-45 clinical study will evaluate the efficacy of treatment with lecanemab in participants with preclinical AD and elevated amyloid and in participants with early preclinical AD and intermediate amyloid. In September 2021, Eisai initiated a rolling submission of a Biologics License Application (BLA) for lecanemab for the treatment of early AD, to the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway.

The Phase 3 AHEAD 3-45 study consists of two sister trials (A3 and A45) with specific dosing regimens tailored to baseline brain amyloid levels on screening PET scans for intermediate amyloid in A3 and for elevated amyloid in A45. In a first-of-a-kind approach in a preclinical trial for AD, the study will seek to determine the potential role of plasma-based biomarkers in the identification of cognitively unimpaired individuals most appropriate to move on to PET imaging, which is currently the standard of care to determine treatment approach.

Blood samples will be collected at a brief initial visit to determine the Abeta42/40 ratio, which has previously been shown to be a potentially reliable predictor of brain amyloid level and is used to determine eligibility to proceed to PET imaging. Based on the PET imaging results, the participants are grouped into A3 or A45 trials.

As of October 18, 2021, data from 659 participants was available for analysis. Adjusted Abeta42/40 ratio demonstrated very good ability to predict amyloid PET eligibility (AUC of 0.87) suggesting plasma screening has potential to substantially reduce number of PET scans needed to fully enroll A3 and A45.

"The screening process for AD can be time consuming and costly. There is a need to accelerate and improve the efficiency of identifying individuals who may be eligible for current and future AD treatments based on cognitive testing and confirmation of elevated amyloid in the brain," said Michael Irizarry, M.D., Vice President, Deputy Chief Clinical Officer, Neurology Business Group, Eisai Inc. "Eisai is forging new ground by incorporating plasma screening in a clinical study for individuals with preclinical AD. We are optimistic that this novel approach will help identify people with elevated brain amyloid, and reduce the need for diagnostic amyloid PET scans or spinal taps."

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.

For more information, visit https://www.eisai.com/news/2021/news202186.html.

Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Lifenet and Eisai Co-Develop Dementia Insurance "be"
March 21 2024 16:36 JST
 
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
March 21 2024 15:10 JST
 
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
March 06 2024 16:47 JST
 
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
February 21 2024 14:26 JST
 
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
February 20 2024 08:35 JST
 
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
February 16 2024 08:31 JST
 
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
February 01 2024 17:04 JST
 
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
January 26 2024 15:26 JST
 
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
January 18 2024 14:12 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
January 17 2024 16:08 JST
 
More Press release >>

Latest Press Release


More Latest Release >>